Xenikos' Series A Round

Xenikos raised a round of funding on June 19, 2012.

Xenikos is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. Once injected in the …

Articles about Xenikos' Series A Round: